AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract. It has a discovery partnership agreement with Eli Lilly and Company. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.
Earnings move Total revenue of $28 million, up from $11 million in Q2 2020 Total programs under contract of 138, up 82% from Q2 2020 Net loss of ($0.01) per share (basic and diluted) compared to net earnings of $0.03 per share (basic and diluted) in Q2 2020
